MRI is another powerful tool to diagnose diffuse liver disease and cancer non-invasively by getting a fast, quantitative, radiation-free image and measurements of the liver. And by automating the image analysis, the clinician has access to fast, consistent, quantifiable, and actionable results within minutes.
From a treatment standpoint, interventional oncology is quickly emerging as a new pillar of cancer care, as many cancer patients are ineligible for surgery. Today, two thirds of interventional oncology procedures are performed on patients with liver cancer.
Historically, clinicians have faced a variety of challenges when treating the liver, including detecting tumor-feeding vessels and determining which injection points will deliver therapies to diseased liver tissue while avoiding the healthy tissue.
New software powered by applied intelligence can help clinicians overcome this hurdle by scanning data from cone beam CT images and providing a nearly-instant analysis of the liver vasculature, automatically highlighting the vessels near tumors.
AI is already improving our ability to assess, diagnose, treat, and monitor liver disease and liver cancer, and healthcare overall. Perhaps in a not too distant future, liver complications can be managed earlier and more efficiently – resulting in millions of lives saved.
Dr. Mathias Goyen, M.D., Ph.D. is the chief medical officer at GE Healthcare
Back to HCB News
